** Shares of Australia's Noxopharm NOX.AX rise 2.1% to A$0.099, their highest level since November 17

** The biotechnology company says the first multiple-dose cohort in the in-human trial for co's autoimmune diseases drug, SOF-SKN, has been successfully completed, bringing co to the final second and final stage of the trial

** Safety Steering Committee has determined the treatment to be safe and well tolerated, with no clinically relevant issues found, co adds

** Stock up 6.5%, YTD

(Reporting by Shruti Agarwal in Bengaluru)

((Shruti.Agarwal@thomsonreuters.com))